BioCentury
ARTICLE | Top Story

Keytruda shows PFS benefit in first-line NSCLC study

June 17, 2016 12:32 AM UTC

Merck & Co. Inc. (NYSE:MRK) said PD-1 inhibitor Keytruda pembrolizumab met the primary endpoint in the Phase III KEYNOTE-024 trial as a first-line therapy for patients with metastatic non-small cell lung cancer with high expression of PD-L1. Keytruda extended progression-free survival, the study's primary endpoint, as well as overall survival (OS) vs. platinum-based therapies. A data monitoring committee recommended that the 305-patient trial be stopped early.

Spokesperson Pam Eisele said Merck plans to present detailed data at a medical meeting this year, and to share the data with regulators "as soon as possible." ...